Medpace (NASDAQ:MEDP) Reaches New 1-Year High Following Strong Earnings

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $677.90 and last traded at $620.5350, with a volume of 153020 shares. The stock had previously closed at $528.12.

The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter last year, the business posted $3.10 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS.

Wall Street Analyst Weigh In

MEDP has been the subject of several analyst reports. BMO Capital Markets lowered their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Mizuho increased their target price on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Barclays lowered their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $473.09.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Medpace

Several institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC lifted its stake in Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after buying an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new position in Medpace during the 2nd quarter worth $296,000. Finally, M&T Bank Corp grew its position in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

The company has a market capitalization of $17.50 billion, a price-to-earnings ratio of 38.34, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. The business’s 50 day simple moving average is $484.63 and its 200 day simple moving average is $493.49.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.